Tandem high-dose therapy with ifosfamide, epirubicin, carboplatin and peripheral blood stem cell support is an effective, adjuvant treatment for high-risk primary breast cancer

European Journal of Cancer Part A

Volumn 33, Issue 3, 1997, Pages 372-378

  Haas, R ^a   Schmid, H ^a   Hahn, U ^a   Hohaus, S ^a   Goldschmidt, H ^a   Murea, S ^a   Kaufmann, M ^b   Wannenmacher, M ^a   Wallwiener, D ^a   Bastert, G ^a   Hunstein, W ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

peripheral blood stem cell support; primary breast cancer; tandem high dose therapy

Indexed keywords

CARBOPLATIN; EPIRUBICIN; GOSERELIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION;

EID: 17644429796     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)89008-9     Document Type: Article

References (24)

1. Bonadonna G. Evolving concepts in systemic adjuvant treatment of breast cancer. Cancer Res. 52:1992;2127-2137.
2. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immunotherapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;1-15.
3. Fisher B, Fisher ER, Redmond C. Ten year results from the NSABP clinical trial evaluating the use of L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. J Clin Oncol. 4:1986;929-941.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 2:1984;1281-1288.
5. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 31:1992;205-213.
6. Peters W, Ross M, Vredenburgh JJ. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 11:1993;1132-1143.
7. Peters W. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: Yes. DeVita VT, Hellman S, Rosenberg SA. Important Advances in Oncology. 1995;215-230 JB Lippincott Company, Philadelphia, PA.
8. Shea TC, Mason JR, Storniolo AM, et al. Sequential cycles of high-dose carboplatin administered with recombinant granulocyte-macrophage colony-stimulating factor and repeated infusion of autologous peripheral blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 10:1992;464-473.
9. Pettengell R, Woll PJ, Thatcher N, et al. Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. J Clin Oncol. 13:1995;148-156.
10. Broun ER, Sridhara R, Sledge GW, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol. 13:1995;2050-2055.
11. Haas R, Möhle R, Frühauf S, et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood. 83:1994;3787-3794.
12. Jain KK, Casper ES, Geller NL. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 3:1985;818-826.
13. Hortobagyi GN, Yap HY, Kau SW, et al. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol. 1:1989;57-62.
14. Elias AD, Ayash LJ, Eder JP, et al. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support. J Clin Oncol. 9:1991;320-327.
15. Hermanek P, Sobin LH. UICC TNM Classification of Malignant Tumours. 1992;Springer, Berlin.
16. Fields KK, Perkins JP, Hiemenz JW, et al. Intensive dose ifosfamide carboplatin, and etoposide followed by autologous stem cell rescue: results of a phase I/II study in breast cancer patients. Surgical Oncol. 2:1993;95-98.
17. Fields KK, Elfenbein GJ, Perkins JB, et al. Two novel high-dose treatment regimens for metastatic breast cancer - ifosfamide, carboplatin, plus etoposide and mitroxantrone plus thiotepa: outcomes and toxicities. Semin Oncol. 20:1993;59-66.
18. Hoffmann W, Weidmann B, Migeod F, et al. Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumors. Cancer Chemother Pharmacol. 26:1990;69-70. (Suppl).
19. Millward MJ, Harris AL, Cantwell BM. Phase II study of doxorubicin plus ifosfamide/mesna in patients with advanced breast cancer. Cancer. 65:1990;2421-2425.
20. Krämer A, Goldschmidt H, Hahn U, Andrassy K. Progressive renal failure in two breast cancer patients after high-dose ifosfamide. Lancet. 344:1994;1569. [Letter].
21. Haas R, Witt B, Möhle R, et al. Sustained long-term hematopoiesis after myeloablative therapy with peripheral blood progenitor cell support. Blood. 85:1995;3754-3761.
22. Buzdar AU, Kau SW, Hortobagyi GN, et al. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 69:1992;448-452.
23. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA. 273:1995;542-547.
24. Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood. 82:1993;2605-2610.